Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)
Neil R. Poulter, MB, MSc*,*,
Joanna E. Dobson, MSc*,
Peter S. Sever, PhD*,
Björn Dahlöf, MD, PhD ,
Hans Wedel, PhD ,
Norm R.C. Campbell, MD on behalf of the ASCOT Investigators
* Imperial College London, London, United Kingdom
Sahlgrenska University Hospital, Göteborg, Sweden
Nordic School of Public Health, Göteborg, Sweden
University of Calgary, Calgary, Alberta, Canada
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Crude Event Rates by Allocated Treatment Group and Baseline Heart Rate Group
Crude event rates/100 person-years and 95% confidence intervals (CIs) (n = 12,759): (A) total cardiovascular events and procedures (1,966 events); (B) nonfatal myocardial infarction (including silent) and fatal coronary heart disease (607 events); (C) total stroke (490 events). bpm = beats/min.
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Hazard Ratios for Allocated Antihypertensive Treatment by Baseline Heart Rate Group
Hazard ratios and 95% CIs after adjusting for all baseline predictors and excluding patients with missing baseline values: (A) total cardiovascular events and procedures outcome; (B) nonfatal myocardial infarction (including silent) and fatal coronary heart disease outcome; (C) total stroke outcome. *Interaction p value is for interaction between continuous heart rate and allocated treatment group. Abbreviations as in Figure 1.
|
|
|
